MedTrace Logo

Acetyl-L-Carnitine In Severe Hepatic Encephalopathy

NCT01223768 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2010-10-19

No results posted yet for this study

Summary

To assess the clinical efficacy of ALC in the treatment of severe hepatic encephalopathy (grade 3 of the West Haven grading scale), we performed a randomised, double blind placebo-controlled study administering ALC to cirrhotic patients, evaluating the effects on ammonia levels and performance in cognitive functions.

Conditions

  • Hepatic Encephalopathy (Grade 3 of the West Haven Grading Scale)

Interventions

DRUG

Acetyl-l-Carnitine

2g per day

DRUG

placebo

twice per day

Sponsors & Collaborators

  • University of Catania

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-31
Completion
2005-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01223768 on ClinicalTrials.gov